Leadership Team

Patrik Brodin, MSc, Ph.D.

Vice President, Head of Radiation Sciences

Patrik Brodin, MSc, Ph.D.

Patrik Brodin, MSc, Ph.D.

Vice President, Head of Radiation Sciences

Patrik is a board certified Medical Physicist, and a Diplomat of the American Board of Radiology in the discipline of Therapeutic Medical Physics, and previously, was an Assistant Professor and Senior Physicist at the department of Radiation Oncology at Montefiore/Einstein. By combining his expertise in radiation physics and data analysis with biology-based research methods, he spearheaded the development of new approaches in radiation-driven immunotherapy, and solutions for reducing the risk of severe treatment complications associated with receiving high-dose radiation therapy. Patrik has experience and expertise in clinical medical physics, biostatistics and advanced analytical methods including quantitative image analysis, and novel experimental design. He has authored more than 60 peer-reviewed publications and presented at national and international meetings including oral presentations at the ESTRO, ASTRO, AAPM and PTCOG annual meetings. Patrik trained in Medical Physics at Lund University, Sweden, followed by a PhD at the Niels Bohr Institute at the University of Copenhagen, Denmark, and received his M.Sc. in Clinical Research Methods from Yeshiva University upon coming to the United States.

Dr. Mary Mei Chen, M.D., Ph.D.

Vice President, Clinical Development

Dr. Mary Mei Chen, M.D., Ph.D.

Dr. Mary Mei Chen, M.D., Ph.D.

Vice President, Clinical Development

Mary leads clinical development programs in hematological malignancies and solid tumors at Actinium Pharmaceuticals, Inc. Prior to joining Actinium, she led multiple clinical trials including the global pivotal Phase 3 study of Uproleselan in AML as well as Phase 1 through Phase 3 clinical trials in patients with multiple myeloma, and solid tumors. She successfully led multidisciplinary teams in the submission of multiple INDs/Clinical Trial Application and participate multiple NDA applications in the US, EU, and other regions at Takeda Inc and Pfizer (Wyeth). She received training in both hematology (M.D.) and immunology (Ph.D.) followed by over twenty years of hematology oncology experience from academics and industry. Before moving her career to industry, she was a faculty, Instructor in Medicine, at Harvard Medical School, Brigham and Women's Hospital. Mary received her Doctor of Medicine degree from Shanghai Jiao Tong University, School of Medicine. and her Ph.D. in Immunology from Chiba University, Graduate School of Medicine in Tokyo, Japan. She completed her postdoctoral fellowship in Harvard Medical School, Boston. Over the course of her career, she has authored over 60 peer reviewed publications in high impact journals.

Avinash Desai, M.D.

Chief Medical Officer

Avinash Desai, M.D.

Avinash Desai, M.D.

Chief Medical Officer

Avinash is an industry veteran in the hematology and oncology field, most recently serving as Vice President, Head of U.S. Medical Affairs – Oncology at Glaxo Smith Kline (GSK). Over the course of his twenty-five-year career, Avinash successfully designed and implemented clinical development, U.S. and global medical affairs, and life cycle management plans for a variety of pharmaceutical products. This has included participation in multiple INDs, NDAs, and sNDA submissions and efficiently managing the product Scientific Advisory Boards (SAB) and Data and Safety Monitoring Boards (DSMB) for hematology, oncology and therapeutic candidates. At GSK, he established the U.S. medical affairs oncology team that oversaw the launch readiness plans for three novel oncology products—Blenrep® in multiple myeloma, Zejula® in ovarian cancer, and dostarlimab in endometrial cancer. In addition to GSK, Avinash has overseen the clinical development, implementation and delivery of oncology life cycle management plans for various oncology therapies at several leading global pharmaceutical companies, including Eli Lilly & Company (Lilly), Janssen Pharmaceuticals, Inc. and Takeda, Inc. Prior to GSK, he was the VP of Global Medical Affairs at Lilly, during which time he oversaw the global medical affairs team for Lilly's GI Oncology portfolio. Earlier in his career, Avinash contributed to the approval of Janssen's myeloma drug Darzalex® (daratumumab) and leading and strategically executing medical affairs activities globally for Velcade® (bortezomib). Prior to Janssen, Avinash was responsible for the international development of oncology products in solid tumors and hematological malignancies at Sanofi, where he successfully executed pivotal trials that led to NDA submission for Jevtana® (cabazitaxel).

Paul Diamond, Ph.D., Esq.

Vice President, Patent and Legal Counsel

Paul Diamond, Ph.D., Esq.

Paul Diamond, Ph.D., Esq.

Vice President, Patent and Legal Counsel

Paul Diamond was appointed Vice President, Patent and Legal Counsel in July 2021.  He brings over twenty years of experience counseling life science companies on complex patent and commercial matters.  Prior to joining Actinium Pharmaceuticals, Paul led the in-house legal team at a publicly traded clinical diagnostics company.  He has practiced with the intellectual property group of global law firm White & Case LLP and at a number of nationally recognized law firms.   Paul received a J.D. from Fordham University School of Law, a Ph.D. (Molecular and Cellular Biology) from Harvard University, and a B.A. (Biology) from the Johns Hopkins University.

Stephen Dressel

Vice President, Strategic Finance & Analysis

Stephen Dressel

Stephen Dressel

Vice President, Strategic Finance & Analysis

Steve has nearly 20 years of corporate finance and commercial experience. He joins from Dewpoint Therapeutics, where he was Senior Director, Financial Planning & Analysis responsible for overseeing budgeting, long-term planning and analyses. Previously, he was Senior Director, Head of Corporate Planning & Operations at Akebia Therapeutics, a publicly traded, commercial-stage company that developed and marketed Auryxia®. Steve spent 10 years at Regeneron in finance roles with increasing responsibility rising to Director, Commercial Finance supporting Praulent and EYLEA, a top 5 biologic launch, where he developed and managed 10-year forecasts and $250 million budgets. He transitioned to commercial roles in the cardiometabolic franchise culminating as Director, Market Access Strategy. He began his career at Bio-IB, a life science focused investment bank, where he helped execute financings, M&A, licensing and corporate advisory assignments. Steve has his MBA from Fordham University and BA degree from the University of Colorado.

Elaina N. Haeuber

Vice President, Head of Clinical Operations

Elaina N. Haeuber

Elaina N. Haeuber

Vice President, Head of Clinical Operations

Elaina brings more than 20 years of clinical research operations and project management experience in the biopharmaceutical industry. Most recently, she was Vice President, Operations at WCG, a global organization supporting various aspects of clinical trials where she was responsible for overseeing data safety monitoring boards and independent event adjudication for numerous clinical studies. Prior to this, she was Executive Director, Operations Management for oncology and hematology trials at Syneos Health. Elaina has overseen regional and global project and clinical management teams of up to 300 staff and managed a strategic biopharma portfolio at PPD, which included more than 60 studies in multiple therapeutic areas.  Her oncology experience includes all phases of studies across multiple indications, cell and gene therapy, immuno- and targeted therapies.  She has supported programs leading to marketing approval in both the US and EMA including PD-L1 inhibitor Tecentriq approved in non-small cell lung cancer, small cell lung cancer, triple negative breast cancer and other indications, Zynteglo, the first cell-based gene therapy approved for patients with beta-thalassemia, and  Skysona, a gene therapy for patients with early, active cerebral adrenoleukodystrophy (CALD). While at PPD, she supported the merger of two independent business units (Acurian and Synexus) into an integrated business unit called Accelerated Enrollment Solutions, as well as played a key role in designing a decentralized clinical trial model to better manage their large clinical trial operations. She has a BA from Boston University and an MS from the University of Illinois.

Jenny Hsieh

Chief Strategy Officer

Jenny Hsieh

Jenny Hsieh

Chief Strategy Officer

Jenny has nearly two decades of experience in leading and developing corporate strategies across the healthcare and life sciences industries. Prior to joining Actinium, Jenny was the Head of Corporate Strategy at Immunomedics and helped transform the clinical-stage company into a commercial organization. Following its FDA approval of Trodelvy®, Immunomedics was acquired by Gilead Sciences for $21 billion. Previously, she was the Director of Corporate Strategy at Quest Diagnostics and a management consultant at several firms, where she advised healthcare and life sciences companies on their strategic plans to drive innovation and meaningful change in the industry. She has a BA from the University of Pennsylvania, an MBA from NYU's Stern School of Business and an MPA from NYU's Wagner Graduate School of Public Service.

Helen Kotanides, Ph.D.

Vice President, Translational Research & Preclinical Development

Helen Kotanides, Ph.D.

Helen Kotanides, Ph.D.

Vice President, Translational Research & Preclinical Development

Helen oversees preclinical research and drug development at Actinium. She brings more than 25 years of Oncology R&D experience from Eli Lilly and ImClone Systems. Prior to joining Actinium, Helen held multiple positions at Eli Lilly culminating as Senior Research Advisor in Cancer Immunobiology. During her career, she focused on preclinical discovery and development of oncology biologic drugs, having led several preclinical programs including the advancement of immune checkpoint therapies and targeted therapies. Helen holds a Ph.D. in Molecular Biology and Biochemistry from the State University of New York at Stony Brook, a M.S in Biology from New York University and B.A in Biology from Clark University.

Sunitha Lakshminarayanan

Senior Vice President, CMC and Product Development

Sunitha Lakshminarayanan

Sunitha Lakshminarayanan

Senior Vice President, CMC and Product Development

Sunitha is a seasoned executive with over 20 years of experience and brings to Actinium broad-based technical expertise across biologics, biosimilars, vaccines and cell/gene therapy products. Prior to joining Actinium, Sunitha was at Bristol-Myers Squibb in their Cell Therapy division, most recently as Executive Director, Global Process Engineering. During her tenure at Celgene/BMS, she was responsible for the global licensure of their two autologous cell therapy products, Breyanzi® and Abecma®. Post-approval, she built the teams that provided support for commercial products. She was also responsible for new cell therapy facility build-outs for network expansions, technology transfers, product life-cycle management, new technology commercialization, comparability, and Global MS&T labs. Prior to BMS, Sunitha was at Kashiv BioSciences where she built the process development and technical services teams, led filing activities, and obtained approvals for Releuko® and Fylnetra®. Prior to Kashiv, Sunitha has held various leadership positions at Progenics Pharmaceuticals, Laureate Pharma and BioReliance. Sunitha earned her MBA from Northwestern University, Master's in Chemical Engineering from Penn State University and BS in Chemical Engineering from the Coimbatore Institute of Technology, India.

Akash Nahar, M.D.

Vice President, Clinical Development

Akash Nahar, M.D.

Akash Nahar, M.D.

Vice President, Clinical Development

Akash has over 15 years of hematology-oncology research and development experience in academia and industry. Previously, Akash held positions of increasing responsibilities, most recently serving as Global Product Development Lead for hematology programs at Merck. In this role, he led a team of six physicians responsible for the development of the PD-1 inhibitor Keytruda® in Hodgkin’s lymphoma along with other developmental products for hematological malignancies. Akash successfully led the filing of two indications for Keytruda®. He made impactful contributions cross-functionally, including clinical research, strategy, and regulatory, spanning multiple hematological indications. He also brings experience from all phases of drug development, successfully executing programs from early phase 1 through approval. Akash is board certified in pediatrics and hematology/oncology. He is a faculty member in oncology at St. Christopher’s Hospital for Children in Philadelphia and an Associate Professor in pediatrics at Drexel University.  He has authored multiple papers and book chapters and have published several papers in peer reviewed journals. Akash received his Bachelor of Medicine and Bachelor or Surgery (MBBS) from Mahatma Gandhi Memorial Medical College, Indore, India and his MPH in Epidemiology from the State University of New York at Albany.

Steve O'Loughlin

Chief Financial Officer

Steve O'Loughlin

Steve O'Loughlin

Chief Financial Officer

Steve joined Actinium in October 2015 as Vice President, Finance and Corporate Development and was named Principal Financial Officer in May 2017 and Chief Financial Officer in July 2020. Steve possesses nearly fifteen years of life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies. Prior to Actinium, from June 2015 to October 2015, Steve worked at J. Streicher LLC as an investment banker, from August 2012 to June 2015 Steve held the position of Vice President, Corporate Finance and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences company developing and commercializing mass spectrometry imaging and bioanalytic technologies and services. Previously, From June 2010 to June 2012, Steve held corporate development positions with Caliber I.D., (formerly Lucid, Inc.) a publicly traded company developing and commercializing VivaScope ®, an FDA cleared diagnostic device for the non-invasive assessment of the skin for skin cancer and other dermatologic conditions. Steve previously worked in investment banking at Jesup & Lamont where he focused on the biotechnology and life sciences industries. Steve has a B.S. in Business Administration with a concentration in finance from Ramapo College of New Jersey.

Monideepa Roy, Ph.D.

Vice President, Corporate Development – R&D

Monideepa Roy, Ph.D.

Monideepa Roy, Ph.D.

Vice President, Corporate Development – R&D

Monideepa leads corporate development initiatives at Actinium, driving business outcomes around R&D efforts. Before joining Actinium, she was Founder and interim CEO of Akamara Therapeutics, Inc., an early-stage oncology drug development company. Prior to Akamara, she was a founding member of Invictus Oncology, developing novel I/O and conjugated antibody therapies. Before moving to industry, Monideepa was a Lecturer at Harvard University, a Leukemia and Lymphoma Society Special Fellow at Brigham and Women’s Hospital and Research Fellow at Harvard Medical School where she was funded by the US Department of Defense and was awarded the first Thomas Gill Prize for Research Excellence. She received her Ph.D. in Molecular Biology from Jawaharlal Nehru University, New Delhi, Master's in Biophysics and Molecular Biology from the University College of Science and Bachelor's degree in Human Physiology (Honors) from Presidency College, Calcutta.

Sandesh Seth

Chief Executive Officer and Chairman of the Board

Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board

Sandesh has 25+ years of experience in investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). Sandesh was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found. Sandesh has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Sandesh was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He has several patents related to use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.

Gary Siegel

Vice President, Controller

Gary Siegel

Gary Siegel

Vice President, Controller

Gary is responsible for the preparation of the Company’s financial reporting, including reports filed with the Securities and Exchange Commission, or SEC. Gary has many years of experience working for public companies. Prior to joining Actinium, he was Controller at Bellerophon Therapeutics, Inc., a public medical device company, and prior to that, he was Vice President Finance of Cogentix Medical, Inc., a public medical device company. From 2003 to 2013, Gary was with Genta Incorporated, a public biopharmaceutical company, where he progressed to be Vice President-Finance and Principal Financial Officer. Earlier in his career, Gary had a number of positions at Pfizer Inc. Gary has an MBA from Carnegie-Mellon University.

Arun Swaminathan, Ph.D.

Chief Business Officer

Arun Swaminathan, Ph.D.

Arun Swaminathan, Ph.D.

Chief Business Officer

Arun oversees all aspects of Business Development strategy and execution at Actinium. Prior to joining Actinium in 2021, he was the Senior VP & Chief Business Officer at Alteogen Inc, where his negotiations with partners led to deals totaling over $6 billion in potential value, including agreements with two of the top ten global pharmaceutical companies. As CEO and co-founder of Lynkogen Inc., he raised capital, in-licensed potentially transformative drug candidates to address complex metabolic diseases and advanced Lynkogen from concept to a pre-clinical stage company with drug candidates that he successfully negotiated for out-licensing. Arun’s earlier experiences include progressive roles in Clinical Pharmacology, Business Development and Marketing at BMS and Head of Marketing of the clinical business at Covance (now Labcorp Drug Development). He holds a Ph.D. in Pharmaceutical Sciences from University of Pittsburgh and is a graduate of the Marketing Management Program from Wharton, University of Pennsylvania.

Madhuri Vusirikala, M.D.

Vice President, Clinical Development BMT and Cellular Therapy

Madhuri Vusirikala, M.D.

Madhuri Vusirikala, M.D.

Vice President, Clinical Development BMT and Cellular Therapy

Madhuri is an accomplished bone marrow transplant physician and hematologist with over 20 years of clinical experience. She is board certified in internal medicine, hematology and oncology. Madhuri joins Actinium from UT Southwestern Medical Center in Dallas, Texas, where she has been a Professor of Internal Medicine in the Division of Hematology/Oncology and Medical Director of the Adult Allogeneic Bone Marrow Transplant Program. She specialized in managing a variety of hematologic malignancies and performing allogeneic bone marrow transplants for these patients when indicated. She also served as primary investigator for most of the clinical trials at UT Southwestern related to BMT. Madhuri earned her medical degree (M.B.B.S.) at India’s Lady Hardinge Medical College before completing an internal medicine internship at Maulana Azad Medical College-Delhi University and an internal medicine internship and residency at The State University of New York, Syracuse. She also completed a hematology and oncology fellowship at the University of Pittsburgh and an advanced fellowship in bone marrow transplantation at Vanderbilt University Medical Center. Madhuri is a member of the American Society of Hematology, American Society of Transplantation and Cellular Therapy. She serves as a member on the NCCN panels for Hematopoietic Cell Transplantation and Acute Lymphoblastic Leukemia committees.

Caroline Yarbrough

Chief Commercial Officer

Caroline Yarbrough

Caroline Yarbrough

Chief Commercial Officer

Caroline is leading the development of Actinium’s commercial strategy and capabilities as it evolves to ensure successful launch and commercialization of Iomab-B and future offerings addressing high unmet needs in cancer. Most recently she was Portfolio General Manager US Oncology at Novartis Innovative Medicines, where she managed a diverse group of brands and development assets. Prior to that she led the CML portfolio team that successfully launched SCEMBLIX® and led account management for KYMRIAH®, the first approved CAR-T cell therapy. Prior to Novartis, Caroline's career spanned multiple large pharmaceutical and biotechnology companies, including Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck, where she held roles with increasing responsibilities in diverse therapeutic areas including oncology, immunology and neuroscience. Caroline has a BA in Biology from University of Delaware, where she received the Peter White Undergraduate Research Fellowship, an MBA from the Goizueta Business School at Emory University and a drs in International Business from Nijenrode University.

Email Sign Up

Receive the latest news, events and updates!

Sign Up Now